Background Acute promyelocytic leukemia (APL) is uncommon among subjects aged >= 70 years and the better therapeutic strategy represents an unmet clinical need. Materials and methods This prompted us to explore our real-life data on a retrospective cohort of 45 older APL patients (>= 70 years) consecutively diagnosed at eight different hematologic institutions in Latium, Italy, from July 1991 to May 2019. Results Two patients (4.4%) died from early hemorrhagic complications before treatment could begin. Twenty-two patients (51.1%) (Group A) were enrolled or treated according to standard clinical protocols, while 21 (48.8%) (Group B) received an ATRA-based personalized approach due to poor performance status. Morphologic complete remission (CR) after induction therapy was achieved in 33 patients (76.7%) with 100% of patients in Group A and 52.3% in Group B (p < 0.001). Molecular CR was documented in 30 patients (69.7%) [20/22 (90.9%) in Group A and 10/21 (47.6%) in Group B (p = 0.002)]. Ten patients (23.2%) died during induction therapy, all in Group B. Five-year overall survival (OS) of the entire cohort was 46.1% (95% CI 28.2-64.0), with 72.6% (95% CI 42.9-100) in Group A vs. 27.2% (95% CI 7.5-46.9) in the Group B (p = 0.001). Conclusions The present analysis highlights that almost half of the patients received sub-optimal induction treatments and registered dismal outcomes demonstrating the importance of adopting standard therapies instead of modified or reduced personalized approaches also in the setting of frail older patients.

Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols / Rosati, Serena; Gurnari, Carmelo; Breccia, Massimo; Carmosino, Ida; Scalzulli, Emilia; Montefusco, Enrico; Perrone, Salvatore; Annibali, Ombretta; Martini, Vincenza; Trapè, Giulio; Colafigli, Gioia; Trawinska, Malgorzata; Minotti, Clara; Cimino, Giuseppe; Tafuri, Agostino; Avvisati, Giuseppe; Martelli, Maurizio; Teresa Voso, Maria; Latagliata, Roberto. - In: ACTA ONCOLOGICA. - ISSN 0284-186X. - (2021). [10.1080/0284186X.2021.1971291]

Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols

Massimo Breccia;Emilia Scalzulli;Enrico Montefusco;Gioia Colafigli;Giuseppe Cimino;Agostino Tafuri;Maurizio Martelli;
2021

Abstract

Background Acute promyelocytic leukemia (APL) is uncommon among subjects aged >= 70 years and the better therapeutic strategy represents an unmet clinical need. Materials and methods This prompted us to explore our real-life data on a retrospective cohort of 45 older APL patients (>= 70 years) consecutively diagnosed at eight different hematologic institutions in Latium, Italy, from July 1991 to May 2019. Results Two patients (4.4%) died from early hemorrhagic complications before treatment could begin. Twenty-two patients (51.1%) (Group A) were enrolled or treated according to standard clinical protocols, while 21 (48.8%) (Group B) received an ATRA-based personalized approach due to poor performance status. Morphologic complete remission (CR) after induction therapy was achieved in 33 patients (76.7%) with 100% of patients in Group A and 52.3% in Group B (p < 0.001). Molecular CR was documented in 30 patients (69.7%) [20/22 (90.9%) in Group A and 10/21 (47.6%) in Group B (p = 0.002)]. Ten patients (23.2%) died during induction therapy, all in Group B. Five-year overall survival (OS) of the entire cohort was 46.1% (95% CI 28.2-64.0), with 72.6% (95% CI 42.9-100) in Group A vs. 27.2% (95% CI 7.5-46.9) in the Group B (p = 0.001). Conclusions The present analysis highlights that almost half of the patients received sub-optimal induction treatments and registered dismal outcomes demonstrating the importance of adopting standard therapies instead of modified or reduced personalized approaches also in the setting of frail older patients.
2021
Acute promyelocytic leukemiaall-trans retinoic acidarsenic trioxideelderly patientsreal-life data
01 Pubblicazione su rivista::01a Articolo in rivista
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols / Rosati, Serena; Gurnari, Carmelo; Breccia, Massimo; Carmosino, Ida; Scalzulli, Emilia; Montefusco, Enrico; Perrone, Salvatore; Annibali, Ombretta; Martini, Vincenza; Trapè, Giulio; Colafigli, Gioia; Trawinska, Malgorzata; Minotti, Clara; Cimino, Giuseppe; Tafuri, Agostino; Avvisati, Giuseppe; Martelli, Maurizio; Teresa Voso, Maria; Latagliata, Roberto. - In: ACTA ONCOLOGICA. - ISSN 0284-186X. - (2021). [10.1080/0284186X.2021.1971291]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1576719
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact